Cryoport, Inc. (NASDAQ:CYRX – Get Rating) – Investment analysts at KeyCorp lowered their FY2024 earnings per share estimates for shares of Cryoport in a research report issued on Thursday, May 5th. KeyCorp analyst P. Knight now expects that the consumer goods maker will post earnings per share of $0.38 for the year, down from their previous estimate of $0.49.
Several other research firms also recently weighed in on CYRX. Needham & Company LLC restated a “buy” rating and set a $45.00 price objective on shares of Cryoport in a report on Wednesday, April 13th. Roth Capital lowered their price objective on shares of Cryoport from $90.00 to $67.00 in a report on Tuesday, May 3rd. TheStreet lowered shares of Cryoport from a “c-” rating to a “d+” rating in a research note on Friday, January 28th. B. Riley reduced their target price on shares of Cryoport from $94.00 to $70.00 in a research note on Wednesday, March 2nd. Finally, SVB Leerink upped their target price on shares of Cryoport from $75.00 to $92.00 and gave the stock an “outperform” rating in a research note on Friday, February 25th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Cryoport presently has a consensus rating of “Buy” and an average price target of $61.14.
Cryoport (NASDAQ:CYRX – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The consumer goods maker reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13). Cryoport had a negative return on equity of 13.57% and a negative net margin of 128.78%. The business had revenue of $52.30 million for the quarter, compared to analyst estimates of $52.86 million. During the same quarter in the previous year, the company posted ($0.13) EPS. The business’s quarterly revenue was down 1.9% on a year-over-year basis.
In related news, CEO Jerrell Shelton sold 3,298 shares of the stock in a transaction dated Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total transaction of $102,402.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert Stefanovich sold 1,095 shares of the stock in a transaction dated Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total transaction of $33,999.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,803 shares of company stock valued at $180,183. 9.70% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Captrust Financial Advisors lifted its holdings in Cryoport by 35.4% during the third quarter. Captrust Financial Advisors now owns 624 shares of the consumer goods maker’s stock valued at $42,000 after purchasing an additional 163 shares during the last quarter. Pinebridge Investments L.P. purchased a new stake in Cryoport during the fourth quarter valued at about $77,000. Lindbrook Capital LLC purchased a new stake in Cryoport during the fourth quarter valued at about $87,000. FinTrust Capital Advisors LLC lifted its holdings in Cryoport by 47.1% during the third quarter. FinTrust Capital Advisors LLC now owns 2,212 shares of the consumer goods maker’s stock valued at $147,000 after purchasing an additional 708 shares during the last quarter. Finally, Parallel Advisors LLC purchased a new stake in Cryoport during the fourth quarter valued at about $158,000.
About Cryoport (Get Rating)
Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.
- Get a free copy of the StockNews.com research report on Cryoport (CYRX)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.